Related references
Note: Only part of the references are listed.Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model
Brian D. VanScoy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Relationship between Gepotidacin Exposure and Prevention of On-Therapy Resistance Amplification in a Neisseria gonorrhoeae Hollow-Fiber In Vitro Infection Model
Brian D. VanScoy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans
Jurgen B. Bulitta et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase
Elizabeth G. Gibson et al.
ACS INFECTIOUS DISEASES (2019)
1482. Microbiological Analysis from a Phase II Study Evaluating Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections
Nicole Scangarella-Oman et al.
Open Forum Infectious Diseases (2019)
Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models
Catharine C. Bulik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Gepotidacin (GSK2140944) In Vitro Activity against Gram-Positive and Gram-Negative Bacteria
R. K. Flamm et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens
D. J. Biedenbach et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with Ceftolozane
Brian VanScoy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Relationship between Ceftolozane-Tazobactam Exposure and Drug Resistance Amplification in a Hollow-Fiber Infection Model
Brian VanScoy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Pharmacodynamics of β-Lactamase Inhibition by NXL104 in Combination with Ceftaroline: Examining Organisms with Multiple Types of β-Lactamases
Arnold Louie et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Type IIA topoisomerase inhibition by a new class of antibacterial agents
Benjamin D. Bax et al.
NATURE (2010)
The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: A new paradigm for optimizing pharmacodynamics to counterselect resistance
Vincent H. Tam et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore
Paul G. Ambrose et al.
CLINICAL INFECTIOUS DISEASES (2007)
Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models
D Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Share Paper
